KKR & Co. Inc.
09/20/2024 | Press release | Distributed by Public on 09/20/2024 00:04
KKR Completes Joint Acquisition of Immedica Pharma
Stockholm and London, 20 September 2024 - KKR, a leading global investment firm, and Impilo, a Nordic healthcare investment firm, have today announced the completion of their joint acquisition of Immedica Pharma, a pharmaceutical company headquartered in Stockholm and focused on the commercialization of medicines for rare diseases and specialty care products.
Having announced the strategic partnership in April this year, KKR and Impilo will continue to work together with Immedica's experienced management team to support the business' growth, as it continues to build on its position as a leader in the European rare disease space.
Kugan Sathiyanandarajah, Partner and Head of KKR's Health Care Strategic Growth business in Europe, commented: "We are excited to close the transaction with Immedica, alongside Impilo. We remain committed to supporting Immedica's future growth as a rare disease player with a highly promising pipeline and attractive international expansion prospects."
Magnus Edlund, Partner at Impilo, commented: "We are eager to now embark on the next phase of Immedica's growth journey together with KKR and management, making innovative medicines available to more patients with high unmet medical needs."
Anders Edvell, CEO of Immedica, commented: "This collaboration with KKR and Impilo marks an exciting step forward in our mission to deliver innovative treatments to more patients with rare diseases. With their support, we are well-positioned to enhance our growth and continue addressing critical unmet medical needs across the globe."
Since its founding in 2018 by Impilo, Immedica has built an impressive portfolio and pipeline of drugs primarily within haematology, oncology and genetic & metabolic diseases for rare conditions with high unmet medical needs, generating revenues of EUR 100m and annual growth of more than 50%.
KKR invested in Immedica through its KKR Health Care Strategic Growth Fund II, a $4.0 billion fund focused on investing in high-growth health care companies. KKR has a long track record of supporting health care companies globally, having invested approximately $20 billion in the sector since 2004.
Impilo re-invested into Immedica through a continuation fund which will enable Impilo to continue supporting Immedica with additional equity alongside KKR.
About KKR:
KKR is a leading global investment firm that offers alternative asset management as well as capital markets and insurance solutions. KKR aims to generate attractive investment returns by following a patient and disciplined investment approach, employing world-class people, and supporting growth in its portfolio companies and communities. KKR sponsors investment funds that invest in private equity, credit and real assets and has strategic partners that manage hedge funds. KKR's insurance subsidiaries offer retirement, life and reinsurance products under the management of Global Atlantic Financial Group. References to KKR's investments may include the activities of its sponsored funds and insurance subsidiaries. For additional information about KKR & Co. Inc. (NYSE: KKR), please visit KKR's website at www.kkr.com. For additional information about Global Atlantic Financial Group, please visit Global Atlantic Financial Group's website at www.globalatlantic.com.
About Impilo:
Impilo is a Nordic investment company focused solely on investments in companies operating in the pharmaceutical, medical technology, healthcare services and other health related industries. Our starting point is that our portfolio companies must contribute to a positive and sustainable development of the societies and markets in which they operate in order to remain successful in the long term. Impilo strives to increase value of its investments through longterm active ownership. Impilo has a well-diversified portfolio of healthcare investments and manages c. EUR 1 billion of capital from leading Nordic and international investors. Learn more about Impilo at www.impilo.se.
Contacts:
Immedica
Linda Holmström, Head of Communications
[email protected]
KKR
Nordics
Fogel & Partners
Ludvig Gauffin
[email protected]
UK
FGS Global
Alastair Elwen
[email protected]
Impilo
Magnus Edlund, Partner
[email protected]
Having announced the strategic partnership in April this year, KKR and Impilo will continue to work together with Immedica's experienced management team to support the business' growth, as it continues to build on its position as a leader in the European rare disease space.
Kugan Sathiyanandarajah, Partner and Head of KKR's Health Care Strategic Growth business in Europe, commented: "We are excited to close the transaction with Immedica, alongside Impilo. We remain committed to supporting Immedica's future growth as a rare disease player with a highly promising pipeline and attractive international expansion prospects."
Magnus Edlund, Partner at Impilo, commented: "We are eager to now embark on the next phase of Immedica's growth journey together with KKR and management, making innovative medicines available to more patients with high unmet medical needs."
Anders Edvell, CEO of Immedica, commented: "This collaboration with KKR and Impilo marks an exciting step forward in our mission to deliver innovative treatments to more patients with rare diseases. With their support, we are well-positioned to enhance our growth and continue addressing critical unmet medical needs across the globe."
Since its founding in 2018 by Impilo, Immedica has built an impressive portfolio and pipeline of drugs primarily within haematology, oncology and genetic & metabolic diseases for rare conditions with high unmet medical needs, generating revenues of EUR 100m and annual growth of more than 50%.
KKR invested in Immedica through its KKR Health Care Strategic Growth Fund II, a $4.0 billion fund focused on investing in high-growth health care companies. KKR has a long track record of supporting health care companies globally, having invested approximately $20 billion in the sector since 2004.
Impilo re-invested into Immedica through a continuation fund which will enable Impilo to continue supporting Immedica with additional equity alongside KKR.
###
About KKR:
KKR is a leading global investment firm that offers alternative asset management as well as capital markets and insurance solutions. KKR aims to generate attractive investment returns by following a patient and disciplined investment approach, employing world-class people, and supporting growth in its portfolio companies and communities. KKR sponsors investment funds that invest in private equity, credit and real assets and has strategic partners that manage hedge funds. KKR's insurance subsidiaries offer retirement, life and reinsurance products under the management of Global Atlantic Financial Group. References to KKR's investments may include the activities of its sponsored funds and insurance subsidiaries. For additional information about KKR & Co. Inc. (NYSE: KKR), please visit KKR's website at www.kkr.com. For additional information about Global Atlantic Financial Group, please visit Global Atlantic Financial Group's website at www.globalatlantic.com.
About Impilo:
Impilo is a Nordic investment company focused solely on investments in companies operating in the pharmaceutical, medical technology, healthcare services and other health related industries. Our starting point is that our portfolio companies must contribute to a positive and sustainable development of the societies and markets in which they operate in order to remain successful in the long term. Impilo strives to increase value of its investments through longterm active ownership. Impilo has a well-diversified portfolio of healthcare investments and manages c. EUR 1 billion of capital from leading Nordic and international investors. Learn more about Impilo at www.impilo.se.
Contacts:
Immedica
Linda Holmström, Head of Communications
[email protected]
KKR
Nordics
Fogel & Partners
Ludvig Gauffin
[email protected]
UK
FGS Global
Alastair Elwen
[email protected]
Impilo
Magnus Edlund, Partner
[email protected]